Recently, CDK1/2/5/9 inhibitor dinaciclib proved to lower CDK7, RET protein and mRNA levels in human MTC cells, showing a synergistic effect when combined with a RET kinase inhibitor [52]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.